Eric V. Krieger

Eric V. Krieger

Auto-generated profile, based on publicly available information

Eric V. Krieger

Division of Cardiology, Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
PCPeter J. Cawley
Peter J. Cawley
Christian Hamilton-CraigChristian Hamilton-Craig
Christian Hamilton-Craig
DODavid S. Owens
David S. Owens
EKEric V. Krieger
Eric V. Krieger
WSWendy E. Strugnell
Wendy E. Strugnell
COCatherine M. Otto
Catherine M. Otto
Background—: Both transthoracic echocardiography (TTE) and cardiac magnetic resonance (CMR) imaging allow quantification of chronic aortic regurgitation (AR) and mitral regurgitation (MR). We hypothesized that CMR measurement of regurgitant volume (RVol) is more reproducible than TTE. Methods and Results—: TTE and CMR performed on the same day in 57 prospectively enrolled adults (31 with AR, 26 with MR) were measured by 2 independent physicians. TTE RVol AR was calculated as Doppler left ventricular outflow minus inflow stroke volume. RVol MR was calculated by both the proximal isovelocity surface area method and Doppler volume flow at 2 sites. CMR RVol AR was calculated by phase-contrast velocity mapping at the aortic sinuses and RVol MR as total left ventricular minus forward stroke volume. Intraobserver and interobserver variabilities were similar. For AR, the Bland–Altman mean interobserver difference in RVol was −0.7 mL (95% confidence interval [CI], −5 to 4) for CMR and −9 mL (95% CI, −53 to −36) for TTE. The Pearson correlation was higher ( P =0.001) between CMR (0.99) than TTE readers (0.89). For MR, the Bland–Altman mean difference in RVol between observers was −4 mL (95% CI, −21 to 13) for CMR compared with 0.7 mL (95% CI, −30 to 32) for the proximal isovelocity surface area and −10 mL (95% CI, −76 to 56) for TTE volume flow at 2 sites. Correlation was similar for CMR (0.94) versus TTE readers (0.90 for the proximal isovelocity surface area). Conclusions—: Compared with TTE, CMR has lower intraobserver and interobserver variabilities for RVol AR , suggesting CMR may be superior for serial measurements. Although RVol MR is similar by TTE and CMR, variability in measured RVol by both approaches suggests that caution is needed in clinical practice.

14 November 2017 in Circulation
Verified
Journal Article
Open access
PDF file
GLGeorge K. Lui
George K. Lui
ASArwa Saidi
Arwa Saidi
ABAmi B. Bhatt
Ami B. Bhatt
LBLuke Burchill
Luke Burchill
JDJason F. Deen
Jason F. Deen
SYShi-Joon Yoo
Shi-Joon Yoo
Life expectancy and quality of life for those born with congenital heart disease (CHD) have greatly improved over the past 3 decades. While representing a great advance for these patients, who have been able to move from childhood to successful adult lives in increasing numbers, this development has resulted in an epidemiological shift and a generation of patients who are at risk of developing chronic multisystem disease in adulthood. Noncardiac complications significantly contribute to the morbidity and mortality of adults with CHD. Reduced survival has been documented in patients with CHD with renal dysfunction, restrictive lung disease, anemia, and cirrhosis. Furthermore, as this population ages, atherosclerotic cardiovascular disease and its risk factors are becoming increasingly prevalent. Disorders of psychosocial and cognitive development are key factors affecting the quality of life of these individuals. It is incumbent on physicians who care for patients with CHD to be mindful of the effects that disease of organs other than the heart may have on the well-being of adults with CHD. Further research is needed to understand how these noncardiac complications may affect the long-term outcome in these patients and what modifiable factors can be targeted for preventive intervention.

1 June 2017 in JACC
Verified
Journal Article
Open access
ZSZachary L. Steinberg
Zachary L. Steinberg
CDClara P. Dominguez-Islas
Clara P. Dominguez-Islas
COCatherine M. Otto
Catherine M. Otto
KSKaren K. Stout
Karen K. Stout
EKEric V. Krieger
Eric V. Krieger
Anticoagulation for mechanical heart valves during pregnancy is essential to prevent thromboembolic events. Each regimen has drawbacks with regard to maternal or fetal risk. This meta-analysis sought to estimate and compare the risk of adverse maternal and fetal outcomes in pregnant women with mechanical heart valves who received different methods of anticoagulation. Studies were identified using a Medline search including all publications up to June 5, 2016. Study inclusion required reporting of maternal death, thromboembolism, and valve failure, and/or fetal spontaneous abortion, death, and congenital defects in pregnant women treated with any of the following: 1) a vitamin K antagonist (VKA) throughout pregnancy; 2) low-molecular-weight heparin (LMWH) throughout pregnancy; 3) LMWH for the first trimester, followed by a VKA (LMWH and VKA); or 4) unfractionated heparin for the first trimester, followed by a VKA (UFH and VKA). A total of 800 pregnancies from 18 publications were included. Composite maternal risk was lowest with VKA (5%), compared with LMWH (16%; ratio of averaged risk [RAR]: 3.2; 95% confidence interval [CI]: 1.5 to 7.5), LMWH and VKA (16%; RAR: 3.1; 95% CI: 1.2 to 7.5), or UFH and VKA (16%; RAR: 3.1; 95% CI: 1.5 to 7.1). Composite fetal risk was lowest with LMWH (13%; RAR: 0.3; 95% CI: 0.1 to 0.8), compared with VKA (39%), LMWH and VKA (23%), or UFH and VKA (34%). No significant difference in fetal risk was observed between women taking ≤5 mg daily warfarin and those with an LMWH regimen (RAR: 0.9; 95% CI: 0.3 to 2.4). VKA treatment was associated with the lowest risk of adverse maternal outcomes, whereas the use of LMWH throughout pregnancy was associated with the lowest risk of adverse fetal outcomes. Fetal risk was similar between women taking ≤5 mg warfarin daily and women treated with LMWH.

13 June 2014 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
DDDao-Fu Dai
Dao-Fu Dai
PSPaul E Swanson
Paul E Swanson
EKEric V Krieger
Eric V Krieger
ILIris W Liou
Iris W Liou
RCRobert L Carithers
Robert L Carithers
MYMatthew M Yeh
Matthew M Yeh
Chronic right heart failure predisposes to hepatic passive congestion and centrizonal necrosis that may lead to hepatic fibrosis (cardiac sclerosis). Although there have been several studies on the histologic features of congestive hepatopathy, there is no available grading system. In this study we developed a novel grading system for congestive hepatic fibrosis. Liver biopsies were examined in patients with chronic heart failure of various etiologies including congenital heart disease, idiopathic cardiomyopathy, ischemic heart disease, and valvular heart disease. The cases with available echocardiography and/or right heart catheterization were included. Cases with other types of underlying chronic liver diseases, alcoholic liver disease, significant steatosis (>20%), malignant neoplasm, and acute heart failure or shock were excluded. After exclusion, 42 cases were included in the study. We herein proposed a novel congestive hepatic fibrosis score and correlated it with the right heart structure and function obtained by echocardiography and/or right heart catheterization. Our results showed that congestive hepatic fibrosis score is well correlated with the right atrial pressure (P for trend <0.001). The presence of portal fibrosis (congestive hepatic fibrosis scores 2 and 3) is associated with significantly higher right atrial pressure than those with no fibrosis (P<0.001) or with centrizonal fibrosis only (P=0.02). Congestive hepatic fibrosis score is also significantly associated with increasing severity of right atrial dilatation (P=0.03) and right ventricular dilatation (P=0.02), indicators for chronic volume and/or pressure overload. Other histopathologic features include sinusoidal dilatation and centrizonal hepatocyte atrophy. In summary, although sinusoidal dilatation and centrizonal fibrosis are the hallmarks of hepatic passive congestion, the presence of portal fibrosis is suggestive of more advanced disease, as it correlates with more severe impairment of right heart function, regardless of the etiologies of right heart failure. Congestive hepatic fibrosis score is a useful indicator of clinical severity.

23 February 2016 in Journal of the American Heart Association
Verified
Journal Article
Open access
JDJason F. Deen
Jason F. Deen
EKEric V. Krieger
Eric V. Krieger
ASApril E. Slee
April E. Slee
AAAlex Arslan
Alex Arslan
DADavid Arterburn
David Arterburn
MPMichael A. Portman
Michael A. Portman
Background: Metabolic syndrome increases risk for atherosclerotic coronary artery disease, and its prevalence increases with increasing age and body mass index. Adults with congenital heart disease ( ACHD ) are now living longer and accruing coronary artery disease risk factors. However, the prevalence of metabolic syndrome in ACHD patients is unknown. Methods and Results: We conducted a retrospective cohort study of ACHD patients at our center to quantify the prevalence of metabolic syndrome in an ACHD population. Using case‐control matching, we constructed a comparable control group from a population‐based sample of 150 104 adults. International Diabetes Federation criteria were used to define metabolic syndrome. We used logistic regression to compare the risk of metabolic syndrome across the resulting cohorts, which were composed of 448 ACHD patients and 448 controls matched by age and sex. Mean age of both groups was 32.4±11.3 years, and 51.3% were female. Obesity was present in 16.1% of the ACHD patients and 16.7% of the controls. Metabolic syndrome was more common in ACHD patients than in controls (15.0% versus 7.4%; odds ratio 1.82, 95% CI 1.25–2.65). Conclusions: Our data suggest that metabolic syndrome is more common among adults with congenital heart disease than in the general population. Thus, patients with congenital heart disease should be screened for metabolic syndrome and risk factors mitigated where possible to prevent atherosclerotic coronary artery disease. Preventive cardiology should be included during routine ACHD care.

29 August 2022 in JACC
Verified
Journal Article
Closed access
CBCraig S. Broberg
Craig S. Broberg
ADAlexandra C. van Dissel
Alexandra C. van Dissel
JMJessica Minnier
Jessica Minnier
JAJamil Aboulhosn
Jamil Aboulhosn
RKRobert M. Kauling
Robert M. Kauling
AOAlexander R. Opotowsky
Alexander R. Opotowsky